Open AccessEffects of Open-Label, Adjunctive Ganaxolone on Persistent Depression Despite Adequate Antidepressant Treatment in Postmenopausal Women
Author(s) -
Laura E. Dichtel,
Maren Nyer,
Christina Dording,
Lauren Fisher,
Cristina Cusin,
Benjamin G. Shapero,
Paola Pedrelli,
Allison Kimball,
Elizabeth Rao,
David Mischoulon,
Maurizio Fava,
Karen K. Miller
Publication year - 2020
Publication title -
the journal of clinical psychiatry/the journal of clinical psychiatry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.677
H-Index - 207
eISSN - 1534-8628
pISSN - 0160-6689
DOI - 10.4088/jcp.19m12887
Subject(s) - allopregnanolone , neuroactive steroid , depression (economics) , antidepressant , major depressive episode , major depressive disorder , medicine , adjunctive treatment , mood , hamilton rating scale for depression , psychology , psychiatry , anxiety , gabaa receptor , receptor , economics , macroeconomics
The neuroactive steroid metabolite of progesterone, allopregnanolone, is a positive allosteric modulator of γ-aminobutyric acid-A (GABAA) receptors and a putative treatment for mood disorders. This pilot study was performed to determine whether an oral allopregnanolone analog (ganaxolone) may be effective adjunctive therapy for persistent depression despite adequate antidepressant treatment in postmenopausal women.